L1PA.F Stock Analysis
L1
Neutral
Based on Eyestock quantitative analysis, L1PA.F`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Lee's Pharmaceutical Holdings Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company employs 1,319 full-time employees The company went IPO on 2002-07-15. The firm operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The firm's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The firm mainly operates its business in mainland China, Hong Kong and Taiwan.